Adult stem cells and biocompatible scaffolds as smart drug delivery tools for cardiac tissue repair

Current Medicinal Chemistry

Volumn 20, Issue 28, 2013, Pages 3429-3447

  Pagliari, Stefania ^a   Romanazzo, Sara ^a   Mosqueira, Diogo ^b   Pinto Do Ó, Perpetua ^b,c   Aoyagi, Takao ^a   Forte, Giancarlo ^a,d  

^a NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Adult stem cells; Biocompatible scaffolds; Cardiac repair; Drug delivery; Genetic modification; Paracrine effect

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR BETA SUBUNIT; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; POLOXAMER; PROTEIN KINASE PIM 1; SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1ALPHA; THYMOSIN BETA4; TISSUE SCAFFOLD; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D;

ADULT STEM CELL; CAPILLARY DENSITY; CELL PROLIFERATION; CELL SURVIVAL; CIRCULATION TIME; CONTROLLED STUDY; DIFFERENTIATION; DNA MODIFICATION; DRUG DELIVERY SYSTEM; FOLLOW UP; GENE EXPRESSION; HEART; HEART DEVELOPMENT; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; HYDROGEL; KIDNEY CLEARANCE; MESENCHYMAL STEM CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN CONFORMATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TISSUE REPAIR; UPREGULATION; WNT SIGNALING PATHWAY;

EID: 84883267656     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990032     Document Type: Review

References (255)

1. Vunjak-Novakovic, G.; Tandon, N.; Godier, A.; Maidhof, R.; Marsano, A.; Martens, T.P.; Radisic, M. Challenges in cardiac tissue engineering. Tissue Eng. Part B. Rev., 2010, 16 (2), 169-187.
2. Forte, G.; Pagliari, S.; Pagliari, F.; Ebara, M.; Di Nardo, P, Aoyagi T. Towards the generation of patient-specific patches for cardiac repair. Stem Cell Rev., 2011, doi: 10.1007/s12015-011-9325-8.
3. Li, T.S.; Cheng, K.; Malliaras, K.; Smith, R.R;, Zhang, Y.; Sun, B.; Matsushita, N.; Blusztajn, A.; Terrovitis, J.; Kusuoka, H.; Marbán, L.; Marbán, E. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol., 2012, 59(10), 942-953.
4. D'Amario D, Cabral-Da-Silva MC, Zheng H, Fiorini C, Goichberg P, Steadman E, Ferreira-Martins J, Sanada F, Piccoli M, Cappetta D, D'Alessandro DA, Michler RE, Hosoda T, Anastasia L, Rota M, Leri A, Anversa P, Kajstura Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. J. Circ. Res., 2011, 108(12), 1467-1481.
5. Angert, D.; Berretta, R.M.; Kubo, H.; Zhang, H.; Chen, X.; Wang, W.; Ogorek, B.; Barbe, M.; Houser, S.R. Repair of the injured adult heart involves new myocytes potentially derived from resident cardiac stem cells. Circ Res., 2011, 108(10), 1226-1237.
6. Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Anderson, S.M.; Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard, B.; Bodine, D.M.; Leri, A.; Anversa, P. Bone marrow cells regenerate infarcted myocardium. Nature, 2001, 410(6829), 701-705.
7. Orlic, D.; Kajstura, J.; Chimenti, S.; Limana, F.; Jakoniuk, I.; Quaini, F.; Nadal-Ginard, B.; Bodine, D.M.; Leri, A.; Anversa, P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. U S A., 2001, 98(18), 10344-10349.
8. Murry, C.E.; Soonpaa, M.H.; Reinecke, H.; Nakajima, H.; Nakajima, H.O.; Rubart, M.; Pasumarthi, K.B.; Virag, J.I.; Bartelmez, S.H.; Poppa, V.; Bradford, G.; Dowell, J.D.; Williams, D.A.; Field, L.J. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature, 2004, 428(6983), 664-668.
9. Balsam, L.B.; Wagers, A.J.; Christensen, J.L.; Kofidis, T.; Weissman, I.L.; Robbins, R.C. Haematopoietic stem cells adopt mature haematopoietic fates in ishaemic myocardium. Nature, 2004, 428(6983), 668-673.
10. Dixon, J.A.; Gorman, R.C.; Stroud, R.E.; Bouges, S.; Hirotsugu, H.; Gorman, J.H. III; Martens, T.P.; Itescu, S.; Schuster, M.D.; Plappert, T.; St John-Sutton, M.G.; Spinale, F.G. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation, 2009, 120(11), S220-S229.
11. Segers, V.F.; Lee, R.T. Stem-cell therapy for cardiac disease. Nature, 2008, 451(7181), 937-942.
12. Dubois, C.; Liu, X.; Claus, P.; Marsboom, G.; Pokreisz, P.; Vandenwijngaert, S.; Depeltau, H.; Streb, W.; Chaothawee, L.; Maes, F.; Gheysens, O.; Debyser, Z.; Gillijns, H.; Pellens, M.; Vandendriessche, T.; Chuah, M.; Collen, D.; Verbeken, E.; Belmans, A.; Van de Werf, F.; Bogaert, J.; Janssens, S. Differential Effects of Progenitor Cell Populations on Left Ventricular Remodeling and Myocardial Neovascularization After Myocardial Infarction. J. Am. Coll. Card., 2010, 55, 2232-2243.
13. Wöhrle, J.; Merkle, N.; Mailänder, V.; Nusser, T.; Schauwecker, P.; von Scheidt, F.; Schwarz, K.; Bommer, M.; Wiesneth, M.; Schrezenmeier, H.; Hombach, V. Results of intracoronary stem cell therapy after acute myocardial infarction. Am. J. Cardiol., 2010, 105(6), 804-812.
14. Beitnes JO, Hopp E, Lunde K, Solheim S, Arnesen H, Brinchmann JE, Forfang K, Aakhus S. Long-term results after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: the ASTAMI randomised, controlled study. Heart, 2009, 95(24), 1983-1939.
15. Tendera M, Wojakowski W, Ruzyłło W, Chojnowska L, Kepka C, Tracz W, Musiałek P, Piwowarska W, Nessler J, Buszman P, Grajek S, Breborowicz P, Majka M, Ratajczak MZ; REGENT Investigators. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur. Heart J., 2009, 30(11), 1313-1321.
16. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J., 2009, 30(24), 2978-2984.
17. Schächinger, V.; Erbs, S.; Elsässer, A.; Haberbosch, W.; Hambrecht, R.; Hölschermann, H.; Yu, J.; Corti, R.; Mathey, D.G.; Hamm, C.W.; Süselbeck, T.; Werner, N.; Haase, J.; Neuzner, J.; Germing, A.; Mark, B.; Assmus, B.; Tonn, T.; Dimmeler, S.; Zeiher, AM; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J., 2006, 27(23), 2775-2783.
18. Beltrami, A.P.; Barlucchi, L.; Torella, D.; Baker, M.; Limana, F.; Chimenti, S.; Kasahara, H.; Rota, M.; Musso, E.; Urbanek, K.; Leri, A.; Kajstura, J.; Nadal-Ginard, B.; Anversa, P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 2003, 114(6), 763-776.
19. Forte, G.; Pietronave, S.; Nardone, G.; Zamperone, A.; Magnani, E.; Pagliari, S.; Pagliari, F.; Giacinti, C.; Nicoletti, C.; Musaró, A.; Rinaldi, M.; Ribezzo, M.; Comoglio, C.; Traversa, E.; Okano, T.; Minieri, M.; Prat, M.; Di Nardo, P. Human cardiac progenitor cell grafts as unrestricted source of supernumerary cardiac cells in healthy murine hearts. Stem Cells, 2011, 29(12), 2051-2061.
20. Hsieh, P.C.; Segers, V.F.; Davis, M.E.; MacGillivray, C.; Gannon, J.; Molkentin, J.D.; Robbins, J.; Lee, R.T. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat. Med., 2007, 13(8), 970-974.
21. Tang, X.L.; Rokosh, G.; Sanganalmath, S.K.; Yuan, F.; Sato, H.; Mu, J.; Dai, S.; Li, C.; Chen, N.; Peng, Y.; Dawn, B.; Hunt, G.; Leri, A.; Kajstura, J.; Tiwari, S.; Shirk, G.; Anversa, P.; Bolli, R. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation, 2010, 121(2), 293-305.
22. Ye, J.; Boyle, A.; Shih, H.; Sievers, R.E.; Zhang, Y.; Prasad, M.; Su, H.; Zhou, Y.; Grossman, W.; Bernstein, H.S.; Yeghiazarians, Y. Sca-1+ cardiosphere-derived cells are enriched for Isl1-expressing cardiac precursors and improve cardiac function after myocardial injury. PLoS One, 2012, 7(1):e30329.
23. Makkar, R.R.; Smith, R.R.; Cheng, K.; Malliaras, K.; Thomson, L.E.; Berman, D.; Czer, L.S.; Marbán, L.; Mendizabal, A.; Johnston, P.V.; Russell, S.D.; Schuleri, K.H.; Lardo, A.C.; Gerstenblith, G.; Marbán, E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet, 2012, 379(9819), 895-904.
24. Chugh, A.R.; Beache, G.M.; Loughran, J.H.; Mewton, N.; Elmore, J.B.; Kajstura, J.; Pappas, P.; Tatooles, A.; Stoddard, M.F.; Lima, J.A.; Slaughter, M.S.; Anversa, P.; Bolli, R. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation, 2012, 126(11 Suppl 1), S54-S64.
25. Terrovitis, J.; Lautamäki, R.; Bonios, M.; Fox, J.; Engles, J.M.; Yu, J.; Leppo, M.K.; Pomper, M.G.; Wahl, R.L.; Seidel, J.; Tsui, B.M.; Bengel, F.M.; Abraham, M.R.; Marbán, E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J. Am. Coll. Cardiol., 2009, 54(17), 1619-1626.
26. Pons, J.; Huang, Y.; Takagawa, J.; Arakawa-Hoyt, J.; Ye, J.; Grossman, W.; Kan, Y.W.; Su, H. Combining angiogenic gene and stem cell therapies for myocardial infarction. J. Gene Med., 2009, 11(9), 743-753.
27. Gnecchi M, He H, liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368.
28. Laflamme, M.A.; Zbinden, S.; Epstein, S.E.; Murry, C.E. Cellbased therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu. Rev. Pathol., 2007, 2, 307-339.
29. Ebelt, H.; Jungblut, M.; Zhang, Y.; Kubin, T.; Kostin, S.; Technau, A.; Oustanina, S.; Niebrügge, S.; Lehmann, J.; Werdan, K.; Braun, T. Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells, 2007, 25(1), 236-244.
30. Martino, G.; Pluchino, S. The therapeutic potential of neural stem cells. Nat. Rev. Neurosci., 2006, 7(5), 395-406.
31. Li, Z.; Guo, J.; Chang, Q.; Zhang, A. Paracrine Role for Mesenchymal Stem Cells in Acute Myocardial Infarction. Biol. Pharm. Bull., 2009, 32(8), 1343-1346.
32. Chimenti, I.; Smith, R.R.; Li, T.S.; Gerstenblith, G.; Messina, E.; Giacomello, A.; Marbán, E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res., 2010, 106(5), 971-980.
33. Urbanek, K.; Rota, M.; Cascapera, S.; Bearzi, C.; Nascimbene, A.; De Angelis, A.; Hosoda, T.; Chimenti, S.; Baker, M.; Limana, F.; Nurzynska, D.; Torella, D.; Rotatori, F.; Rastaldo, R.; Musso, E.; Quaini, F.; Leri, A.; Kajstura, J.; Anversa, P. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res., 2005, 97(7), 663-673.
34. Hatzistergos, K.E.; Quevedo, H,; Oskouei, B.N.; Hu, Q.; Feigenbaum, G.S.; Margitich, I.S.; Mazhari, R.; Boyle, A.J.; Zambrano, J.P.; Rodriguez, J.E.; Dulce, R.; Pattany, P.M.; Valdes, D.; Revilla, C.; Heldman, A.W.; McNiece, I.; Hare, J.M. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res., 2010, 107(7), 913-922.
35. Ellison, G.M.; Torella, D.; Dellegrottaglie, S.; Perez-Martinez, C.; Perez de Prado, A.; Vicinanza, C.; Purushothaman, S.; Galuppo, V.; Iaconetti, C.; Waring, C.D.; Smith, A,; Torella, M.; Cuellas Ramon, C.; Gonzalo-Orden, J.M.; Agosti, V.; Indolfi, C.; Galiñanes, M.; Fernandez-Vazquez, F.; Nadal-Ginard, B. Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. J Am Coll Cardiol., 2011, 58(9), 977-986.
36. Hwang, H.; Kloner, R.A. Improving regenerating potential of the heart after myocardial infarction: factor-based approach. Life Sci., 2010, 86(13-14), 461-472.
37. Hausenloy, D.J.; Yellon, D.M. Cardioprotecive growth factors. Cardiovasc. Res., 2009, 83(2), 179-194.
38. Takeda, Y,; Uemura, S.; Iwama, H.; Imagawa, K.; Nishida, T.; Onoue, K.; Takemoto, Y.; Soeda, T.; Okayama, S.; Somekawa, S.; Ishigami, K.; Takaoka, M.; Kawata, H.; Kubo, A.; Horii, M.; Nakajima, T.; Saito, Y. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J., 2009, 73(9), 1674-1682.
39. Milla, P.; Dosio, F.; Cattel, L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab., 2012, 13(1), 105-119.
40. Hwang, H.; Kloner, R.A. The combined administration of multiple soluble factors in the repair of chronically infarcted rat myocardium. J. Cardiovasc. Pharmacol., 2011, 57(3), 282-286.
41. Leor, J.; Ansalem, Y.; Cohen, S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol. Ther., 2005, 105(2), 151-163.
42. Madonna, R.; Rokosh, G.; De Caterina, R.; Bolli, R. Hepatocyte growth factor/Met gene transfer in cardiac stem cells - potential for cardiac repair. Basic Res. Cardiol., 2010, 105(4), 443-452.
43. Jin, H.; Wyss, J. M.; Yang, R.; Schwall, R. The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure. Curr. Pharm. Des., 2004, 10(20), 2525-2533.
44. Taniyama, Y.; Morishita, R.; Aoki, M.; Nakagami. H.; Yamamoto, K.; Yamazaki, K.; Matsumoto, K.; Nakamura, T.; Kaneda, Y.; Ogihara, T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther., 2001, 8(3), 181-189.
45. Grant, D.S.; Kleinman, H.K.; Goldberg, I.D.; Bhargava, M.M.; Nickoloff, B.J.; Kinsella, J.L.; Polverini, P.; Rosen, E.M. Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci. U S A, 1993, 90(5), 1937-1941.
46. Bussolino, F.; Di Renzo, M.F.; Ziche, M.; Bocchietto, E.; Olivero, M.; Naldini, L.; Gaudino, G.; Tamagnone, L.; Coffer, A.; Comoglio, P.M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol., 1992, 119(3), 629-641.
47. Van Belle, E.; Witzenbichler, B.; Chen, D.; Silver, M.; Chang, L.; Schwall, R.; Isner, J.M. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation, 1998, 97(4), 381-390.
48. Nakamura, T.; Mizuno, S.; Matsumoto, K.; Sawa, Y.; Matsuda, H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest., 2000, 106(12), 1511-1519.
49. Pietronave, S.; Forte, G.; Locarno, D.; Merlin, S.; Zamperone, A.; Nicotra, G.; Isidoro, C.; Di Nardo, P.; Prat, M. Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(4), H1155-H1165.
50. Yasuda, S.; Goto, Y.; Baba, T.; Satoh, T.; Sumida, H.; Miyazaki, S.; Nonogi, H. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J. Am. Coll. Cardiol., 2000, 36(1), 115-121.
51. Nakamura, T.; Matsumoto, K.; Mizuno, S.; Sawa, Y.; Matsuda, H.; Nakamura T. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am. J. Physiol. Heart Circ. Physiol., 2005, 288(5), H2131-H2139.
52. Taniyama, Y.; Morishita, R.; Nakagami, H.; Moriguchi, A.; Sakonjo, H.; Shokei-Kim; Matsumoto, K.; Nakamura, T.; Higaki, J.; Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation, 2000, 102(2), 246-252.
53. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.; Pessina, G.; Pandolfi, S.; Natoni, F.; Di Febo, A.; Scambia, G.; Manfredini, R.; Salati, S.; Ferrari, S.; Pierelli, L.; Leone, G.; Lemoli, R.M. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108(1), 218-227.
54. Forte, G.; Minieri, M.; Cossa, P.; Antenucci, D.; Sala, M.; Gnocchi, V.; Fiaccavento, R.; Carotenuto, F.; De Vito, P.; Baldini, P.M. Prat, M.; Di Nardo, P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells, 2006, 24(1), 23-33.
55. Fiaccavento, R.; Carotenuto, F.; Minieri, M.; Fantini, C.; Forte, G.; Carbone, A.; Carosella, L.; Bei, R.; Masuelli, L.; Palumbo, C.; Modesti, A.; Prat, M.; Di Nardo, P. Stem cell activation sustains hereditary hypertrophy in hamster cardiomyopathy. J. Pathol., 2005, 205(3), 397-407.
56. Olsson, A.K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling -in control of vascular function. Nat. Rev. Mol. Cell Biol., 2006, 7(5), 359-371.
57. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev., 2004, 56(4), 549-580.
58. Giordano, F.J.; Gerber, H.P.; Williams, S.P.; VanBruggen, N.; Bunting, S.; Ruiz-Lozano, P.; Gu, Y.; Nath, A.K.; Huang, Y.; Hickey, R.; Dalton, N.; Peterson, K.L.; Ross, J.Jr.; Chien, K.R.; Ferrara, N. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl. Acad. Sci. U S A, 2001, 98(10), 5780-5785.
59. Liu, S.Q.; Tefft, B.J.; Zhang, D.; Roberts, D.; Schuster, D.J.; Wu, A.; Cardioprotective mechanisms activated in response to myocardial ischemia. Mol. Cell Biomech., 2011, 8(4), 319-338.
60. Tomanek, R.J.; Lund, D.D.; Yue, X. Hypoxic induction of myocardial vascularization during development. Adv. Exp. Med. Biol., 2003, 543, 139-149.
61. Lian, F.; Xue, S.; Gu, P.; Zhu, H.S. The long-term effect of autologous endothelial progenitor cells from peripheral blood implantation on infarcted myocardial contractile force. J. Int. Med. Res., 2008, 36(1), 40-46.
62. Zhou, L.; Ma, W.; Yang, Z.; Zhang, F.; Lu, L.; Ding, Z.; Ding, B.; Ha, T.; Gao, X.; Li, C. VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways. Gene Ther., 2005, 12(3), 196-202.
63. Nör, J.E.; Christensen, J.; Mooney, D.J.; Polverini, P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol., 1999, 154(2), 375-384.
64. Simón-Yarza, T.; Formiga, F.R.; Tamayo, E.; Pelacho, B.; Prosper, F.; Blanco-Prieto, M.J. Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics, 2012, 2(6), 541-552.
65. Ylä-Herttuala, S.; Rissanen, T.T.; Vajanto, I.; Hartikainen, J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol., 2007, 49(10), 1015-1026.
66. Yun, Y.R.; Won, J.E.; Jeon, E.; Lee.; Kang, W.; Jo, H.; Jang, J.H.; Shin, U.S.; Kim, H.W. Fibroblast growth factors: biology, function, and application for tissue regeneration. J. Tissue Eng., 2010, 2010, 218142.
67. Szebenyi, G.; Fallon, J.F. Fibroblast growth factors as multifunctional signaling factors. Int. Rev. Cytol., 1999, 185, 45-106.
68. Zhao, T.; Zhao, W.; Chen, Y.; Ahokas, R.A.; Sun, Y. Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int. J. Cardiol., 2011, 152(3), 307-313.
69. Rosenblatt-velin, N.; Lepore, M. G.; Cartoni, C.; Beermann, F. Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J. Clin. Invest., 2005, 115(7), 1724-1733.
70. Takehara, N.; Tsutsumi, Y.; Tateishi, K.; Ogata, T.; Tanaka, H.; Ueyama, T.; Takahashi, T.; Takamatsu, T.; Fukushima, M.; Komeda, M.; Yamagishi, M.; Yaku, H.; Tabata, Y.; Matsubara, H.; Oh, H. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J. Am. Coll. Cardiol., 2008, 52(23), 1858-1865.
71. Nishida, S.; Nagamine, H.; Tanaka, Y.; Watanabe, G. Protective effect of basic fibroblast growth factor against myocyte death and arrhythmias in acute myocardial infarction in rats. Circ. J., 2003, 67(4), 334-339.
72. Edelberg, J.M; Cai, D.; Xaymardan, M. Translation of PDGF cardioprotective pathways. Cardiovasc. Toxicol., 2003, 3(1), 27-35.
73. Edelberg, J.M.; Aird, W.C.; Wu, W.; Rayburn, H.; Mamuya, W.S.; Mercola, M.; Rosenberg, R.D. PDGF mediates cardiac microvascular communication. J. Clin. Invest., 1998, 102(4), 837-843.
74. Edelberg, J.M.; Tang, L.; Hattori, K.; Lyden, D.; Rafii, S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ. Res., 2002, 90(10), E89-E93.
75. Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S, Bramwell O, Wong SC, Hong MK. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation, 2002, 105(5), 608-613.
76. Xaymardan, M.; Tang, L.; Zagreda, L.; Pallante, B.; Zheng, J.; Chaze, J.L.; Chin, A.; Duignan, I.; Nahirney, P.; Rafii, S.; Mikawa, T.; Edelberg, J.M. Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes. Circ. Res., 2004, 94(5), E39-45.
77. Nienaber, C.A.; Petzsch, M.; Kleine, H.D.; Eckard, H.; Freund, M.; Ince, H. Effects of granulocyte-colony-stimulating factor on mobilization of bone-marrow-derived stem cells after myocardial infarction in humans. Nat. Clin. Pract. Cardiovasc. Med., 2006, 3 (Suppl 1), S73-S77.
78. Boneberg, E.M.; Hartung, T. Molecular aspects of antiinflammatory action of G-CSF. Inflamm. Res., 2002, 51(3), 119-128.
79. Anderlini, P.; Przepiorka, D.; Champlin, R.; Körbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood, 1996, 88(8), 2819-2825.
80. Haas, R.; Murea, S. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells. Cytokines Mol. Ther., 1995, 1(4), 249-270.
81. Erratum in Cytokines Mol. Ther., 1996, 2(1), 136.
82. Kastrup, J.; Ripa, R.S.; Wang, Y.; Jørgensen, E. Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischemic heart disease: a non-invasive alternative for clinical stem cell therapy? Eur. Heart J., 2006, 27(23), 2748-2754.
83. Takano, H.; Ueda, K.; Hasegawa, H.; Komuro, I. G-CSF therapy for acute myocardial infarction. Trends Pharmacol. Sci., 2007, 28(10), 512-517.
84. Hasegawa, H.; Takano, H.; Iwanaga, K.; Ohtsuka, M.; Qin, Y.; Niitsuma, Y.; Ueda, K.; Toyoda, T.; Tadokoro, H.; Komuro, I. Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J. Am. Coll. Cardiol., 2006, 47(4), 842-849.
85. Zohlnhöfer, D.; Kastrati, A.; Schömig, A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4 (Suppl 1), S106-S109.
86. Lapidot, T.; Petit, I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol., 2002, 30(9), 973-981.
87. Orlic, D.; Kajstura, J.; Chimenti, S.; Limana, F.; Jakoniuk, I.; Quaini, F.; Nadal-Ginard, B.; Bodine, D.M.; Leri, A.; Anversa, P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. U S A, 2001, 98(18), 10344-10349.
88. Harada, M.; Qin, Y.; Takano, H.; Minamino, T.; Zou, Y.; Toko, H.; Ohtsuka, M.; Matsuura, K.; Sano, M.; Nishi, J.; Iwanaga, K.; Akazawa, H.; Kunieda, T.; Zhu.; Hasegawa, H.; Kunisada, K.; Nagai, T.; Nakaya, H.; Yamauchi-Takihara, K.; Komuro, I. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat. Med., 2005, 11(3), 305-311.
89. Kanellakis, P.; Slater, N.J.; Du, X.J.; Bobik, A.; Curtis, D.J. Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Cardiovasc. Res., 2006, 70(1), 117-125.
90. Hamamoto, M.; Tomita, S.; Nakatani, T.; Yutani, C.; Yamashiro, S.; Sueda, T.; Yagihara, T.; Kitamura, S. Granulocyte-colony stimulating factor directly enhances proliferation of human troponin I-positive cells derived from idiopathic dilated cardiomyopathy through specific receptors. J. Heart Lung Transpl., 2004, 23(12), 1430-1437.
91. Shimoji, K.; Yuasa, S.; Onizuka, T.; Hattori, F.; Tanaka, T.; Hara, M.; Ohno, Y.; Chen, H.; Egasgira, T.; Seki, T.; Yae, K.; Koshimizu, U.; Ogawa, S.; Fukuda, K. G-CSF promotes the proliferation of developing cardiomyocytes in vivo and in derivation from ESCs and iPSCs. Cell Stem Cell, 2010, 6(3), 227-237.
92. Baldo, M.P.; Davel, A.P.; Damas-Souza, D.M.; Nicoletti-Carvalho, J.E.; Bordin, S.; Carvalho, H.F.; Rodrigues, S.L.; Rossoni, L.V.; Mill, J.G. The antiapoptotic effect of granulocyte colonystimulating factor reduces infarct size and prevents heart failure development in rats. Cell Physiol. Biochem., 2011, 28(1), 33-40.
93. Deindl, E.; Zaruba, M.M.; Brunner, S.; Huber, B.; Mehl, U.; Assmann, G.; Hoefer, I.E.; Mueller-Hoecker, J.; Franz, W.M. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J., 2006, 20(7), 956-958.
94. Achilli, F.; Malafronte, C.; Lenatti, L.; Gentile, F.; Dadone, V.; Gibelli, G.; Maggiolini, S.; Squadroni, L.; Di Leo, C.; Burba, I.; Pesce, M.; Mircoli, L.; Capogrossi, M.C.; Di Lelio, A.; Camisasca, P.; Morabito, A.; Colombo, G.; Pompilio, G,; STEM-AMI Investigators. Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur. J. Heart Fail., 2010, 12(10), 1111-1121.
95. Kurdi M, Booz GW. G-CSF-based therapy for the heart-unresolved issues part A: paracrine actions, mobilization, and delivery. Congest. Heart Fail., 2008, 13(4), 221-227.
96. Engelmann, M.G.; Theiss, H.D.; Hennig-Theiss, C.; Huber, A.; Wintersperger, B.J.; Werle-Ruedinger, A.E.; Schoenberg, S.O.; Steinbeck, G.; Franz, W.M. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol., 2006, 48(8), 1712-1721.
97. Ghadge, S.K.; Mühlstedt, S.; Ozcelik, C.; Bader, M. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacol. Ther., 2011, 129(1), 97-108.
98. Askari, A.T.; Unzek, S.; Popovic, Z.B.; Goldman, C.K.; Forudi, F.; Kiedrowski, M.; Rovner, A.; Ellis, S.G.; Thomas, J.D.; DiCorleto, P.E.; Topol, E.J.; Penn, M.S. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischemic cardiomyopathy. Lancet, 2003, 362(9385), 697-703.
99. Zaruba, M.M.; Franz, W.M. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert. Opin. Biol. Ther., 2010, 10(3), 321-335.
100. Zaruba, M.M.; Theiss, H.; Vallaster, M.; Mehl, U.; Brunner, S.; David, R.; Fischer, R.; Krieg, L.; Hirsch, E.; Huber, B.; Nathan, P.; Israel, L.; Imhof, A.; Herbach, N.; Assmann, G.; Wanke, R.; Mueller-Hoecker, J.; Steinbeck, G.; Franz, W.M. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell, 2009, 4(4), 313-323.
101. Theiss, H.D.; Vallaster, M.; Rischpler, C.; Krieg, L.; Zaruba, M.M.; Brunner, S.; Vanchev, Y.; Fischer, R.; Gröbner, M.; Huber, B.; Wollenweber, T.; Assmann, G.; Mueller-Hoecker, J.; Hacker, M.; Franz, W.M. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res., 2011, 7(3), 244-255.
102. Hwang, M.W.; Matsumori.; Furukawa, Y.; Ono, K.; Okada, M.; Iwasaki, A.; Hara, M.; Miyamoto, T.; Touma, M.; Sasayama, S. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J. Am. Coll. Cardiol., 2001, 38(5), 1546-1553.
103. Toldo, S.; Mezzaroma, E.; Van Tassell, B.W.; Farkas, D.; Marchetti, C.; Voelkel, N.F.; Abbate, A. Interleukin-1β immunoneutralization improves cardiac remodeling after myocardial infarction without interrupting the inflammasome in the mouse. Exp. Physiol., 2012, doi: 10.1113/expphysiol.2012. 069831.
104. Mountain, D.J.; Singh, M.; Singh, K. Interleukin-1beta-mediated inhibition of the processes of angiogenesis in cardiac microvascular endothelial cells. Life Sci., 2008, 82(25-26), 1224-1230.
105. Mountain, D.J.; Singh, M.; Singh, K. Downregulation of VEGF-D expression by interleukin-1beta in cardiac microvascular endothelial cells is mediated by MAPKs and PKCalpha/beta1. J. Cell Physiol., 2008, 215(2), 337-343.
106. Mountain, D.J.; Singh, M.; Menon, B.; Singh, K. Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am. J. Physiol. Cell Physiol., 2007, 292(2), C867-C875.
107. Rosell, A.; Arai, K.; Lok, J.; He, T.; Guo, S.; Navarro, M.; Montaner, J.; Katusic, Z.S.; Lo, E.H. Interleukin-1beta augments angiogenic responses of murine endothelial progenitor cells in vitro. J. Cereb. Blood Flow Metab., 2009, 29(5), 933-943.
108. Xie, Z.; Singh, M.; Singh, K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1beta. J. Biol. Chem., 2004, 279(38), 39513-39519.
109. Chablais, F.; Jazwinska, A. The regenerative capacity of the zebrafish heart is dependent on TGFβ signaling. Development, 2012, 139(11), 1921-1930.
110. Bujak, M.; Frangogiannis, N.G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res., 2007, 74(2), 184-195.
111. Dobaczewski, M.; Chen, W.; Frangogiannis, N.G. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J. Mol. Cell Cardiol., 2011, 51(4), 600-606.
112. 1 oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart. PLoS One, 2011, 6(11), e26628.
113. Orlova, V.V.; Liu, Z.; Goumans, M.J.; ten Dijke, P. Controlling angiogenesis by two unique TGF-β type I receptor signaling pathways. Histol. Histopathol., 2011, 26(9), 1219-1230.
114. Dobaczewski, M.; Bujak, M.; Li, N.; Gonzalez-Quesada, C.; Mendoza, L.H.; Wang, X.F.; Frangogiannis, N.G. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res., 2010, 107(3), 418-428.
115. Doyle, B.; Sorajja, P.; Hynes, B.; Kumar, A.H.; Araoz, P.A.; Stalboerger, P.G.; Miller, D.; Reed, C.; Schmeckpeper, J.; Wang, S.; Liu, C.; Terzic, A.; Kruger, D.; Riederer, S.; Caplice, N.M. Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev., 2008, 17(5), 941-951.
116. Chen, L.L.; Yin, H.; Huang, J. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis. Cardiovasc. Pathol., 2007, 16(4), 221-230.
117. Holifield, J.S.; Arlen, A.M.; Runyan, R.B.; Tomanek, R.J. TGFbeta1, -beta2 and-beta3 cooperate to facilitate tubulogenesis in the explanted quail heart. J. Vasc. Res., 2004, 41(6), 491-498.
118. Rosenkranz, S.; Flesch, M.; Amann, K.; Haeuseler, C.; Kilter, H.; Seeland, U.; Schlüter, K.D.; Böhm, M. Alterations of betaadrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am. J. Physiol. Heart Circ. Physiol., 2002, 283(3), H1253-H1262.
119. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res., 2002, 53(1), 31-47.
120. Krishnamurthy, P.; Lambers, E.; Verma, S.; Thorne, T.; Qin, G.; Losordo, D.W.; Kishore, R. Myocardial knockdown of mRNAstabilizing protein HuR attenuates post-MI inflammatory response and left ventricular dysfunction in IL-10-null mice. FASEB J., 2010, 24(7), 2484-2494.
121. Dewald, O.; Ren, G.; Duerr, G.D.; Zoerlein, M.; Klemm, C.; Gersch, C.; Tincey, S.; Michael, L.H.; Entman, M.L.; Frangogiannis, N.G. Of mice and dogs:
122. Frangogiannis, N.G.; Mendoza, L.H.; Lindsey, M.L.; Ballantyne, C.M.; Michael, L.H.; Smith, C.W.; Entman, M.L. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J. Immunol., 2000, 165(5), 2798-2808.
123. Zymek, P.; Nah, D.Y.; Bujak, M.; Ren, G.; Koerting, A.; Leucker, T.; Huebener, P.; Taffet, G.; Entman, M.; Frangogiannis, N.G. Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodeling. Cardiovasc. Res., 2007, 74(2), 313-322.
124. Yang, Z.; Zingarelli, B.; Szabó, C. Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation, 2000, 101(9), 1019-1026.
125. Burchfield, J.S.; Iwasaki, M.; Koyanagi, M.; Urbich, C.; Rosenthal, N.; Zeiher, A.M.; Dimmeler, S. Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res., 2008, 103(2), 203-211.
126. Krishnamurthy, P.; Thal, M.; Verma, S.; Hoxha, E.; Lambers, E.; Ramirez, V.; Qin, G.; Losordo, D.; Kishore, R. Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium. Circ. Res., 2011, 109(11), 1280-1289.
127. Meldrum, D.R. Tumor necrosis factor in the heart. Am. J. Physiol., 1998, 274(3 Pt 2), R577-595.
128. Kleinbongard, P.; Schulz, R.; Heusch, G. TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail. Rev., 2011, 16(1), 49-69.
129. Bajaj, G.; Sharma, R.K. TNF-alpha-mediated cardiomyocyte apoptosis involves caspase-12 and calpain. Biochem. Biophys. Res. Commun., 2006, 345(4), 1558-1564.
130. Mann, D.L.; McMurray, J.J.; Packer, M.; Swedberg, K.; Borer, J.S.; Colucci, W.S.; Djian, J.; Drexler, H.; Feldman, A.; Kober, L.; Krum, H.; Liu, P.; Nieminen, M.; Tavazzi, L.; van Veldhuisen, D.J.; Waldenstrom, A.; Warren, M.; Westheim, A.; Zannad, F.; Fleming, T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation, 2004, 109(13), 1594-1602.
131. Wang, M.; Markel, T.; Crisostomo, P.; Herring, C.; Meldrum, K.K.; Lillemoe, K.D.; Meldrum, D.R. Deficiency of TNFR1 protects myocardium through SOCS3 and IL-6 but not p38 MAPK or IL-1beta. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(4), H1694-H1699.
132. Higuchi, Y.; McTiernan, C.F.; Frye, C.B.; McGowan, B.S.; Chan, T.O.; Feldman, A.M. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation, 2004, 109(15) 1892-1897.
133. Sugano, M.; Tsuchida, K.; Hata, T.; Makino, N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J., 2004, 18(7), 911-913.
134. Sugano, M.; Koyanagi, M.; Tsuchida, K.; Hata, T.; Makino, N. In vivo gene transfer of soluble TNF-alpha receptor 1 alleviates myocardial infarction. FASEB J., 2002, 16(11), 1421-1422.
135. Paige, S.L.; Osugi, T.; Afanasiev, O.K.; Pabon, L.; Reinecke, H.; Murry, C.E. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One, 2010, 5(6), e11134.
136. Oerlemans, M.I.; Goumans, M.J.; van Middelaar, B.; Clevers, H.; Doevendans, P.A.; Sluijter, J.P. Active Wnt signaling in response to cardiac injury. Basic Res. Cardiol., 2010, 105(5), 631-641.
137. Tzahor, E. Wnt/beta-catenin signaling and cardiogenesis: timing does matter. Dev. Cell, 2007, 13(1), 10-13.
138. Hermans, K.C.; Daskalopoulos, E.P.; Blankesteijn, W.M. Interventions in Wnt signaling as a novel therapeutic approach to improve myocardial infarct healing. Fibrogenesis Tissue Repair., 2012, 5(1), 16.
139. Laeremans, H.; Hackeng, T.M.; van Zandvoort, M.A.; Thijssen, V.L.; Janssen, B.J.; Ottenheijm, H.C.; Smits, J.F.; Blankesteijn, W.M. Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation, 2011, 124(15), 1626-1635.
140. Saraswati, S.; Alfaro, M.P.; Thorne, C.A.; Atkinson, J.; Lee, E.; Young, P.P. Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS One, 2010, 5(11), e15521.
141. He, W.; Zhang, L.; Ni, A.; Zhang, Z.; Mirotsou, M.; Mao, L.; Pratt, R.E.; Dzau, V.J. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl. Acad. Sci. U S A, 2010, 107(49), 21110-21115.
142. Alfaro, M.P.; Pagni, M.; Vincent, A.; Atkinson, J.; Hill, M.F.; Cates, J.; Davidson, J.M.; Rottman, J.; Lee, E.; Young, P.P. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc. Natl. Acad. Sci. U S A, 2008, 105(47), 18366-18371.
143. Barandon, L.; Casassus, F.; Leroux, L.; Moreau, C.; Allières, C.; Lamazière, J.M.; Dufourcq, P.; Couffinhal, T.; Duplàa, C. Secreted frizzled-related protein-1 improves postinfarction scar formation through a modulation of inflammatory response. Arterioscler. Thromb. Vasc. Biol., 2011, 31(11), e80-e87.
144. Barandon, L.; Couffinhal, T.; Ezan, J.; Dufourcq, P.; Costet, P.; Alzieu, P.; Leroux, L.; Moreau, C.; Dare, D.; Duplàa, C. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation, 2003, 108(18), 2282-2289.
145. Zelarayán, L.C.; Noack, C.; Sekkali, B.; Kmecova, J.; Gehrke, C.; Renger, A.; Zafiriou, M.P.; van der Nagel, R.; Dietz, R.; de Windt, L.J.; Balligand, J.L.; Bergmann, M.W. Beta-Catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc. Natl. Acad. Sci. U S A, 2008, 105(50), 19762-19767.
146. Cittadini, A.; Strömer, H.; Katz, S.E.; Clark, R.; Moses, A.C.; Morgan, J.P.; Douglas, P.S. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation, 1996, 93(4), 800-809.
147. Millis, R.M.; Alvin, Z.V.; Zhao, A;. Haddad, G.E. Effects of IGF-1 on I(K) and I(K1) Channels via PI3K/Akt Signaling in Neonatal Cardiac Myocytes. Int. J. Cell Biol., 2012, doi: 10.1155/2012/712153.
148. Zhang, Y.; Yuan, M.; Bradley, K.M.; Dong, F.; Anversa, P.; Ren, J. Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function. Hypertension, 2012, 59(3), 680-693.
149. O'Sullivan, J.F.; Leblond, A.L.; Kelly, G.; Kumar, A.H.; Metharom, P.; Büneker, C.K.; Alizadeh-Vikali, N.; Hristova, I.; Hynes, B.G.; O'Connor, R.; Caplice, N.M. Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circ. Cardiovasc. Interv., 2011, 4(4), 327-335.
150. Accornero, F.; Molkentin, J.D. Placental growth factor as a protective paracrine effector in the heart. Trends Cardiovasc. Med., 2011, 21(8), 220-224.
151. Iwama, H.; Uemura, S.; Naya, N.; Imagawa, K.; Takemoto, Y.; Asai, O.; Onoue, K.; Okayama, S.; Somekawa, S.; Kida, Y.; Takeda, Y.; Nakatani, K.; Takaoka, M.; Kawata, H.; Horii, M.; Nakajima, T.; Doi, N.; Saito, Y. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J. Am. Coll. Cardiol., 2006, 47(8), 1559-1567.
152. Miura, T.; Miki, T. GSK-3beta, a therapeutic target for cardiomyocyte protection. Circ. J., 2009, 73(7), 1184-1192.
153. Sugden, P.H.; Fuller, S.J.; Weiss, S.C.; Clerk, A. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br. J. Pharmacol., 2008, 153(Suppl 1), S137-S153.
154. Cheng, H.; Woodgett, J.; Maamari, M.; Force, T. Targeting GSK-3 family members in the heart: a very sharp double-edged sword. J. Mol. Cell Cardiol., 2011, 51(4), 607-613.
155. Hardt, S.E.; Sadoshima, J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res., 2002, 90(10), 1055-1063.
156. Stiehler, M.; Duch, M.; Mygind, T.; Li, H.; Ulrich-Vinther, M.; Modin, C.; Baatrup, A.; Lind, M.; Pedersen, F.S.; Bünger, C.E. Optimizing viral and non-viral gene transfer methods for genetic modification of porcine mesenchymal stem cells. Adv. Exp. Med. Biol., 2006, 585, 31-48.
157. Wasala, N.B.; Shin, J.H.; Duan, D. The evolution of heart gene delivery vectors. J. Gene Med., 2011, 13(10), 557-565.
158. Haider, H.Kh.; Jiang, S.; Idris, N.M.; Ashraf, M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ. Res., 2008, 103(11), 1300-1308.
159. Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu Z, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol. Cells, 2005, 19(3), 402-407.
160. Cho, J.; Zhai, P.; Maejima, Y.; Sadoshima, J. Myocardial injection with GSK-3b-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ. Res., 2011, 108(4), 478-489.
161. Duan, H.F.; Wu, C.T.; Wu, D.L.; Lu, Y.; Liu, H.J.; Ha, X.Q.; Zhang, Q.W.; Wang, H.; Jia, X.X.; Wang, L.S. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol. Ther., 2003, 8(3), 467-474.
162. Zhu, X.Y.; Zhang, X.Z.; Xu, L.; Zhong, X.Y.; Ding, Q.; Chen, Y.X. Transplantation of adipose-derived stem cells overexpressing hHGF into cardiac tissue. Biochem. Biophys. Res. Commun., 2009, 379(4), 1084-1090.
163. Melly, L.; Marsano, A.; Frobert, A.; Boccardo, S.; Helmrich, U.; Heberer, M.; Eckstein, F.S.; Carrel, T.P.; Giraud, M.N.; Tevaearai, H.T.; Banfi, A. Controlled angiogenesis in the heart by cell-based expression of specific VEGF levels. Hum. Gene Ther. Methods, 2012, 23(5), 346-356.
164. Matsumoto, R.; Omura, T.; Yoshiyama, M.; Hayashi, T.; Inamoto, S.; Koh, K.R.; Ohta, K.; Izumi, Y.; Nakamura, Y.; Akioka, K.; Kitaura, Y.; Takeuchi, K.; Yoshikawa, J. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 2005, 25(6), 1168-1173.
165. Tang, J.M.; Wang, J.N.; Zhang, L.; Zheng, F.; Yang, J.Y.; Kong, X.; Guo, L.Y.; Chen, L.; Huang, Y.Z.; Wan, Y.; Chen, S.Y.VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc. Res., 2011, 91(3), 402-411.
166. Zhang, M.; Mal, N.; Kiedrowski, M.; Chacko, M.; Askari, A.T.; Popovic, Z.B.; Koc, O.N.; Penn, M.S. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J., 2007, 21(12), 3197-3207.
167. Paul, A.; Nayan, M.; Khan, A.A.; Shum-Tim, D.; Prakash, S. Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction. Int. J. Nanomed., 2012, 7, 663-682.
168. Bai, X.; Yan, Y.; Song, Y.; Seidensticker, M.; Rabinovich, B.; Metzele, R.; Bankson, J.A.; Vykoukal, D.; Alt, E. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur. Heart J., 2010, 31(4), 489-501.
169. Yang, J.J.; Yang, X.; Liu, Z.Q.; Hu, S.Y.; Du, Z.Y.; Feng, L.L.; Liu, J.F.; Chen, Y.D. Transplantation of adipose tissue-derived stem cells overexpressing heme oxygenase-1 improves functions and remodeling of infarcted myocardium in rabbits. Tohoku J. Exp. Med., 2012, 226(3), 231-241.
170. Tang, Y.L.; Tang, Y.; Zhang, Y.C.; Qian, K.; Shen, L.; Phillips, M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol., 2005, 46(7), 1339-1350.
171. She, Q.; Xia, S.; Deng, S.B.; Du, J.L.; Li, Y.Q.; He, L.; Xiao, J.; Xiang, Y.L. Angiogenesis in a rat model following myocardial infarction induced by hypoxic regulation of VEGF165 genetransfected EPCs. Mol. Med. Report., 2012, 6(6), 1281-1287.
172. Das, H.; George, J.C.; Joseph, M.; Das, M.; Abdulhameed, N.; Blitz, A.; Khan, M.; Sakthivel, R.; Mao,H. Q.; Hoit, B.D.; Kuppusamy, P.; Pompili, V.J. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One, 2009, 4(10), e7325.
173. Becker, C.; Lacchini, S.; Muotri, A.R.; da Silva, G.J.; Castelli, J.B.; Vassallo, P.F.; Menck, C.F.; Krieger, J.E. Skeletal muscle cells expressing VEGF induce capillary formation and reduce cardiac injury in rats. Int. J. Cardiol., 2006, 113(3), 348-354.
174. Gmeiner, M.; Zimpfer, D.; Holfeld, J.; Seebacher, G.; Abraham, D.; Grimm, M.; Aharinejad, S. Improvement of cardiac function in the failing rat heart after transfer of skeletal myoblasts engineered to overexpress placental growth factor. J. Thorac. Cardiovasc. Surg., 2011, 141(5), 1238-1245.
175. Xiang, G.; Yang, Q.; Wang, B.; Sekiya, N.; Mu, X.; Tang, Y.; Chen, C.W.; Okada, M.; Cummins, J.; Gharaibeh, B.; Huard, J. Lentivirus-mediated Wnt11 gene transfer enhances Cardiomyogenic differentiation of skeletal muscle-derived stem cells. Mol. Ther., 2011, 19(4), 790-796.
176. Menasché, P. Skeletal myoblasts and cardiac repair. J. Mol. Cell Cardiol., 2008, 45(4), 545-553.
177. Reinecke, H.; Minami, E.; Virag, J.I.; Murry, C.E. Gene transfer of connexin43 into skeletal muscle. Hum. Gene Ther., 2004, 15(7), 627-636.
178. Yao, J.; Jiang, S.L.; Liu, W.; Liu, C.; Chen, W.; Sun, L.; Liu, K.Y.; Jia, Z.B.; Li, R.K.; Tian, H. Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res., 2012, 15(5), 495-506.
179. Fazel, S.S.; Angoulvant, D.; Butany, J.;Weisel, R.D.; Li, R.K. Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential. J. Thorac. Cardiovasc. Surg., 2008, 136(5), 1388-1389.
180. Li, W.; Ma, N.; Ong, L.L.; Nesselmann, C.; Klopsch, C.; Ladilov, Y.; Furlani, D.; Piechaczek, C.; Moebius, J.M.; Lützow, K.; Lendlein, A.; Stamm, C.; Li, R.K.; Steinhoff, G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells, 2007, 25(8), 2118-2127.
181. Gnecchi, M.; He, H.; Melo, L.G.; Noiseaux, N.; Morello, F.; de Boer, R.A.; Zhang, L.; Pratt, R.E.; Dzau, V.J.; Ingwall, J.S. Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells, 2009, 27(4), 971-979.
182. Mangi, A.A.; Noiseux, N.; Kong, D.; He, H.; Rezvani, M.; Ingwall, J.S.; Dzau, V.J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med., 2003, 9(9), 1195-1201.
183. Gnecchi, M.; He, H.; Liang, O.D.; Melo, L.G.; Morello, F.; Mu, H.; Noiseux, N.; Zhang, L.; Pratt, R.E.; Ingwall, J.S.; Dzau, V.J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med., 2005, 11(4), 367-368.
184. Lim, S.Y.; Kim, Y.S.; Ahn, Y.; Jeong, M.H.; Hong, M.H.; Joo, S.Y.; Nam, K.I.; Cho, J.G.; Kang, P.M.; Park, J.C. The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc. Res., 2006, 70(3), 530-542.
185. Fischer, K.M.; Cottage, C.T.; Wu, W.; Din, S.; Gude, N.A.; Avitabile, D.; Quijada, P.; Collins, B.L.; Fransioli, J.; Sussman, M.A. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation, 2009, 120(21), 2077-2087.
186. Cho, Y.H.; Cha, M.J.; Song, B.W.; Kim, I.K.; Song, H.; Chang, W.; Lim, S.; Ham, O.; Lee, S.Y.; Choi, E.; Kwon, H.M.; Hwang, K.C. Enhancement of MSC adhesion and therapeutic efficiency in ischemic heart using lentivirus delivery with periostin. Biomaterials, 2012, 33(5), 1376-1385.
187. Li, H.; Zuo, S.; He, Z.; Yang, Y.; Pasha, Z.; Wang, Y.; Xu, M. Paracrine factors released by GATA-4 overexpressed mesenchymal stem cells increase angiogenesis and cell survival. Am. J. Physiol. Heart. Circ. Physiol., 2010, 299(6), H1772-H1781.
188. Rysä, J.; Tenhunen, O.; Serpi, R.; Soini, Y.; Nemer, M.; Leskinen, H.; Ruskoaho, H. GATA-4 is an angiogenic survival factor of the infarcted heart. Circ. Heart Fail., 2010, 3(3), 440-450.
189. Wang, Y.; Luther, K. Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway. Prog Mo. Bio. Trans. Sci., 2012, 111, 265-284.
190. Ruvinov, E.; Leor, J.; Cohen, S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials, 2011, 32(2), 565-578.
191. Fujita, M.; Ishihara, M.; Morimoto, Y.; Simizu, M.; Saito, Y.; Yura, H.; Matsui, T.; Takase, B.; Hattori, H.; Kanatani, Y.; Kikuchi, M.; Maehara, T. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2in a rabbit model of chronic myocardial infarction. J. Surg. Res., 2005, 126(1), 27-33.
192. Tambara, K.; Premaratne, G.U.; Sakaguchi, G.; Kanemitsu, N.; Lin, X.; Nakajima, H.; Sakakibara, Y.; Kimura, Y.; Yamamoto, M.; Tabata, Y.; Ikeda, T.; Komeda, M. Administration of controlreleased hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation, 2005, 112(9 Suppl), I129-1134.
193. Schmaljohann, D. Thermo- and pH-responsive polymers in drug delivery. Adv. Drug Deliv. Rev., 2006, 58(15), 1655-1670.
194. Lee, K.; Silva, E.A.; Mooney, D.J. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J. R. Soc. Interface, 2011, 8(55), 153-170.
195. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B. Biointerfaces, 2010, 75(1), 1-18.
196. Panyam, J.; Labhasetwara, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 55(3), 329-347.
197. Muller, R.H.; Keck, C.M. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur. J. Pharm. Biopharm., 2012, 80(1), 1-3.
198. Tessmar, J.K.; Göpferich, A.M. Matrices and scaffolds for protein delivery in tissue engineering. Adv. Drug Deliv. Rev., 2007, 59(4-5), 274-291.
199. Anderson, J.M. Biological responses to materials. Annu. Rev. Mat. Sci., 2001, 31, 81-110.
200. Anderson, J.M.; Rodriguez, A.; Chang, D.T. Foreign body reaction to biomaterials. Semin Immunol., 2008, 20(2), 86-100.
201. Di Felice, V.; De Luca, A.; Serradifalco, C.; Di Marco, P.; Verin, L.; Motta, A.; Guercio A.; Zummo, G. Adult stem cells, scaffolds for in vivo and in vitro myocardial tissue engineering. Ital. J. Anat. Embryol., 2010, 115(1-2), 65-69.
202. Luttikhuizen, D.T.; van Amerongen, M.J.; de Feijter, P.C.; Petersen, A.H.; Harmsen, M.C.; van Luyn, M.J.A. The correlation between difference in foreign body reaction between implant locations and cytokine and MMP expression. Biomaterials, 2006, 27, 5763-5770.
203. Pagliari, S.; Vilela-Silva, A.C.; Forte, G.; Pagliari, F.; Mandoli, C.; Vozzi, G.; Pietronave, S.; Prat, M.; Licoccia, S.; Ahluwalia, A.; Traversa, E.; Minieri, M.; Di Nardo, P. Cooperation of biological and mechanical signals in cardiac progenitor cell differentiation. Adv Mater., 2011, 23(4), 514-518.
204. Mooney, D.; Vandenburgh, H. Cell delivery Mechanisms for tissue repair. Cell Stem Cell, 2008, 2(3), 205-213.
205. Segers, V.F.; Lee, R.T. Biomaterials to enhance stem cell function in the heart. Circ. Res., 2011, 109(8), 910-922.
206. Sun, Q.; Silva, E.A.; Wang, A.; Fritton, J.C.; Mooney, D.J.; Schaffler, M.B.; Grossman, P.M.; Rajagopalan, S. Sustained release of multiple growth factors from injectable polymeric system as a novel therapeutic approach towards angiogenesis. Pharm. Res., 2010, 27(2), 264-271.
207. Burdick, J.A.; Vunjak-Novakovic, G. Engineered microenvironments for controlled stem cell differentiation. Tissue Eng. Part A., 2009, 5(2), 205-219.
208. Cao, L.; Mooney, D.J. Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv. Drug Deliv. Rev., 2007, 59(13), 1340-1350.
209. Richardson, T.P.; Peters, M.C.; Ennett, A.B.; Mooney, D.J. Polymeric system for dual growth factor delivery. Nat. Biotechnol., 2001, 19(11), 1029-1034.
210. Discher, D.E.; Mooney, D.J.; Zandstra, P.W. Growth factors, matrices and forces combine and control stem cells. Science, 2009, 324 (5935), 1673-1677.
211. Chien, K.R.; Domian, I.J.; Parker, K.K. Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science, 2008, 322 (5907), 1494-1497.
212. Lutolf, M.P.; Hubbel, J.A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol., 2005, 23(1), 47-55.
213. Miyagi, Y.; Chiu, L.L.; Cimini, M.; Weisel, R.D.; Radisic, M.; Li, R.K. Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials, 2011, 32(5), 1280-1290.
214. Wang, Y.; Liu, X.C.; Zhao, J.; Kong, X.R.; Shi, R.F.; Zhao, X.B.; Song, C.X.; Liu, T.J.; Lu, F. Degradable PLGA scaffolds with basic fibroblast growth factor: experimental studies in myocardial revascularization. Tex. Heart Inst. J., 2009, 36(2), 89-97.
215. Miyagi, Y.; Zeng, F.; Huang, X.P.; Foltz, W.D.; Wu, J.; Mihic, A.; Yau, T.M.; Weisel, R.D.; Li, R.K. Surgical ventricular restoration with a cell- and cytokine-seeded biodegradable scaffold. Biomaterials, 2010, 31(30), 7684-7694.
216. Dvir, T.; Kedem, A.; Ruvinov, E.; Levy, O.; Freeman, I.; Landa, N.; Holbova, R.; Feinberg, M.S.; Dror, S.; Etzion, Y.; Leor, J.; Cohen, S. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proc. Natl. Acad. Sci. U S A, 2009, 106(135), 14990-14995.
217. Holladay, C.A.; Duffy, A.M.; Chen, X.; Sefton, M.V.; O'Brien, T.D.; Pandit, A.S. Recover of cardiac function mediated by MSC and interleukin-10 plasmid functionalized scaffold. Biomaterials, 2012, 33(5), 1303-1314.
218. Polizzotti, B.D.; Arab, S.; Kühn, B. Intrapericardial delivery of gelfoam enables the targeted delivery of Periostin peptide after myocardial infarction by inducing fibrin clot formation. PLoS One, 2012, 7(5), e36788.
219. Seliktar, D. Designing cell-compatible hydrogels for biomedical applications. Science, 2012, 336(6085), 1124-1128.
220. Zhu, J.; Marchant, R.E. Design properties of hydrogel tissueengineering scaffolds. Expert. Rev. Med. Devices, 2011, 8(5), 607-626.
221. Baroli B. Hydrogels for tissue engineering and delivery of tissueinducing substances. J. Pharm. Sci., 2007, 96(9), 2197-2223.
222. Srivastava, D.; Saxena, A, Michael Dimaio, J.; Bock-Marquette, I. Thymosin beta4 is cardioprotective after myocardial infarction. Ann. N. Y. Acad. Sci., 2007, 1112, 161-170.
223. Chiu, L.L.; Reis, L.A.; Momen, A.; Radisic, M. Controlled release of thymosin β4 from injected collagen-chitosan hydrogels promotes angiogenesis and prevents tissue loss after myocardial infarction. Regen. Med., 2012, 7(4), 523-533.
224. Censi, R.; Di Martino, P.; Vermonden, T.; Hennink, W.E. Hydrogels for protein delivery in tissue engineering. J. Control Release, 2012, 161(2), 680-692.
225. Drury, J.L.; Mooney, D.J. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials, 2003, 24(24), 4337-4351.
226. Ohya, S.; Matsuda, T. Poly(N-isopropylacrylamide) (PNIPAM)-grafted gelatin as thermoresponsive three-dimensional artificial extracellular matrix: molecular and formulation parameters vs. cell proliferation potential. J. Biomater. Sci. Polym. Ed., 2005, 16(7), 809-827.
227. Kim, S.; Chung, E.H.; Gilbert, M.; Healy, K.E. Synthetic MMP-13 degradable ECMs based on poly(N-isopropylacrylamide-co-acrylic acid) semi-interpenetrating polymer networks. I. Degradation and cell migration. J. Biomed. Mater. Res. A., 2005, 75(1), 73-88.
228. Wang, F.; Li, Z.; Khan, M.; Tamama, K.; Kuppusamy, P.; Wagner, W.R.; Sen, C.K.; Guan, J. Injectable, rapid gelling and highly flexible hydrogel composites as growth factor and cell carriers. Acta Biomater., 2010, 6(6), 1978-1991.
229. Shapira-Schweitzer, K.; Habib, M.; Gepstein, L.; Seliktar, D. A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells. J. Mol. Cell Cardiol., 2009, 46(2), 213-224.
230. + cell homing to the infarcted heart. Tissue Eng., 2007, 13(8), 2063-2076.
231. Zhang, G.E.; Hu, Q.; Braunlin, E.A.; Suggs, L.J.; Zhang, J. Enhancing efficacy of stem cell transplantation to the heart with PEGylated fibrin biomatrix. Tissue Eng. Part A., 2008, 14(6), 1025-1037.
232. Zhao, X.; Pan, F.; Xu, H.; Yaseen, M.; Shan, H.; Hauser, C.A.; Zhang, S.; Lu, J.R. Molecular self-assembly and applicantions of designer peptide amphiphiles. Chem. Soc. Rev., 2010, 39(9), 3480-3498.
233. Hsieh, P.C.; Davis, M.E.; Gannon, J.; MacGillivray, C.; Lee, R.T. Controlled delivery of PDGF-BB for myocardial protection using injectable self assembling peptide nanofibers. J. Clin. Invest., 2006, 116(1), 237-248.
234. Davis, M.E.; Hsieh, P.C.; Takahashi, T.; Song, Q.; Zhang, S.; Kamm, R.D.; Grodzinsky, A.J.; Anversa, P.; Lee, R.T. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. USA, 2006, 103(21), 8155-8160.
235. Padin-Iruegas, M.E.; Misao, Y.; Davis, M.E.; Segers, V.F.; Esposito, G.; Tokunou, T.; Urbanek, K.; Hosoda, T.; Rota, M.; Anversa, P.; Leri, A.; Lee, R.T.; Kajstura, J. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation, 2009, 120(10), 876-887.
236. Segers, V.F.; Tokunou, T.; Higgins, L.J.; MacGillivray, C.; Gannon, J.; Lee, R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation, 2007, 116(15), 1683-1692.
237. Mahapatro, A.; Singh, D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnol., 2011, 9, 55.
238. Holladay, C.A.; O'Brien, T.; Pandit, A. Non-viral gene therapy for myocardial engineering. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2(3), 232-248.
239. Yockman, J.W.; Kastenmeier, A.; Erickson, H.M.; Brumbach, J.G.; Whitten, M.G.; Albanil, A.; Li, D.Y.; Kim, S.W.; Bull, D.A. Novel Polymer Carriers and Gene Constructs for Treatment of Myocardial Ischemia and Infarction. J. Control Release, 2008, 132(3), 260-266.
240. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target specific nanoparticles: theory to practice, Pharmacol. Rev., 2001, 53(2), 283-318.
241. Kawabata, Y.; Wada, K.; Nakatani, M.; Yamada, S.; Onoue, S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm., 2011, 420(1), 1-10.
242. Vauthier, C.; Bouchemal, K. Methods for the Preparation and Manufacture of Polymeric Nanoparticles. Pharm. Res., 2009, 26(5), 1025-1058.
243. Godin, B.; Sakamoto, J.H.; Serda, R.E.; Grattoni, A.; Bouamrani, A.; Ferrari, M. Emerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseases. Trends Pharmacol. Sci., 2010, 31(5), 199-205.
244. Galagudza, M.M.; Korolev, D.V.; Sonin, D.L.; Postnov, V.N.; Papayan, G.V.; Uskov, I.S.; Belozertseva, A.V.; Shlyakhto, E.V. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int. J. Nanomed., 2010, 5, 231-237.
245. Galagudza, M.; Korolev, D.; Postnov, V.; Naumisheva, E.; Grigorova, Y.; Uskov, I.; Shlyakhto, E. Passive targeting of ischemicreperfused myocardium with adenosine-loaded silica nanoparticles. Int. J. Nanomed., 2012, 7, 1671-1678.
246. Levchenko, T.S.; Hartner, W.C.; Torchilin, V.P. Liposomes for cardiovascular targeting. Ther. Deliv., 2012, 3(4), 501-514.
247. Scott, R.C.; Rosano, J.M.; Ivanov, Z.; Wang, B.; Chong, P.L.; Issekutz, A.C.; Crabbe, D.L.; Kiani, M.F. Targeting VEGFencapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J., 2009, 23(10), 3361-3367.
248. Oh, K.S.; Song, J.Y.; Yoon, S.J.; Park, Y.; Kim, D.; Yuk, S.H. Temperature-induced gel formation of core/shell nanoparticles for the regeneration of ischemic heart. J. Control Release, 2010, 46(2), 207-211.
249. Radomski, A.; Jurasz, P.; Alonso-Escolano, D.; Drews, M.; Morandi, M.; Malinski, T.; Radomski, M.W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol., 2005, 146(6), 882-893.
250. Karam, J.P.; Muscari, C.; Montero-Menei, C.M. Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium. Biomaterials, 2012, 33(23), 5683-5695.
251. Cittadini, A.; Monti, M.G.; Petrillo, V.; Esposito, G.; Imparato, G.; Luciani, A.; Urciuolo, F.; Bobbio, E.; Natale, C.F.; Saccà, L.; Netti, P.A. Complementary therapeutic effects of dual delivery of insulinlike growth factor-1 and vascular endothelial growth factor by gelatin microspheres in experimental heart failure. Eur. J. Heart Fail., 2011, 13(12), 1264-1274.
252. Banquet, S.; Gomez, E.; Nicol, L.; Edwards-Lévy, F.; Henry, J.P.; Cao, R.; Schapman, D.; Dautreaux, B.; Lallemand, F.; Bauer, F.; Cao, Y.; Thuillez, C.; Mulder, P.; Richard, V.; Brakenhielm, E. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation, 2011, 124(9), 1059-1069.
253. Sy, J.C.; Seshadri, G.; Yang, S.C.; Brown, M.; Oh, T.; Dikalov, S.; Murthy, N.; Davis, M.E. Sustained release of a p38 inhibitor from non-inflammatory microspheres inhibits cardiac dysfunction. Nat. Mater., 2008, 7(11), 863-868.
254. Gray, W.D.; Che, P.; Brown, M.; Ning, X.; Murthy, N.; Davis, M.E. N-acetylglucosamine conjugated to nanoparticles enhances myocyte uptake and improves delivery of a small molecule p38 inhibitor for post-infarct healing. Cardiovasc. Transl. Res., 2011, 4(5), 631-643.
255. Formiga, F.R.; Pelacho, B.; Garbayo, E.; Abizanda, G.; Gavira, J.J.; Simon-Yarza, T.; Mazo, M.; Tamayo, E.; Jauquicoa, C.; Ortizde-Solorzano, C.; Prósper, F.; Blanco-Prieto, M.J. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J. Control Release, 2010, 147(1), 30-37.